Answers are grounded in this paper and cite their sources.
Neoadjuvant chemotherapy (NACT) can facilitate tumor downstaging in operable hormone receptor-positive/ human epidermal growth factor receptor 2 (HER2)-negative breast cancer, whereas comparisons of long-term outcome with adjuvant chemotherapy (ACT) inform treatment selection. We compared NACT and ACT in a multicenter retrospective cohort of 2,355 women treated at five Chinese centers between 2013 and 2019. Inverse probability of treatment weighting was used to improve the balance of measured baseline characteristics. After weighting, NACT was associated with shorter disease-free survival (hazard ratio [HR] 1.73, 95% confidence interval [CI] 1.26–2.37, p = 0.001) and overall survival (HR 1.85, 95% CI 1.18–2.90, p = 0.007) compared with ACT. Among patients receiving NACT, adverse associations with survival were more pronounced in clinical nonresponders than in responders. These observational findings suggest that post-treatment clinical response may help stratify prognosis after NACT and support the consideration of baseline risk and expected response when selecting the chemotherapy sequence.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: